AR074816A1 - Anticuerpo anti- idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloide - Google Patents

Anticuerpo anti- idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloide

Info

Publication number
AR074816A1
AR074816A1 ARP090104999A ARP090104999A AR074816A1 AR 074816 A1 AR074816 A1 AR 074816A1 AR P090104999 A ARP090104999 A AR P090104999A AR P090104999 A ARP090104999 A AR P090104999A AR 074816 A1 AR074816 A1 AR 074816A1
Authority
AR
Argentina
Prior art keywords
antibody
directed against
beta
peptide
idiotipo
Prior art date
Application number
ARP090104999A
Other languages
English (en)
Inventor
Kay-Gunnar Stubenrauch
Rudolf Vogel
Ulrich Essig
Wolfgang Hoesel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR074816A1 publication Critical patent/AR074816A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpo antiidiotipo que se une a la región determinante de la complementariedad de un anticuerpo dirigido contra el péptido beta-amiloide. En una realización, dicho anticuerpo se une al mismo epítopo o a un epítopo solapado que el anticuerpo obtenible de la línea celular DSM ACC2939. También se describe un inmunoensayo para la determinación de un anticuerpo dirigido contra el péptido beta-amiloide y para la determinación de un anticuerpo antiidiotipo que se une a un anticuerpo dirigido contra el péptido beta-amiloide.
ARP090104999A 2008-12-22 2009-12-21 Anticuerpo anti- idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloide AR074816A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08022235 2008-12-22

Publications (1)

Publication Number Publication Date
AR074816A1 true AR074816A1 (es) 2011-02-16

Family

ID=40581970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104999A AR074816A1 (es) 2008-12-22 2009-12-21 Anticuerpo anti- idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloide

Country Status (22)

Country Link
US (2) US8614297B2 (es)
EP (1) EP2379601B1 (es)
JP (1) JP5642702B2 (es)
KR (2) KR20110086182A (es)
CN (2) CN106990251B (es)
AR (1) AR074816A1 (es)
AU (1) AU2009331900A1 (es)
BR (1) BRPI0923544B1 (es)
CA (1) CA2746779C (es)
CY (1) CY1118420T1 (es)
DK (1) DK2379601T3 (es)
ES (1) ES2595981T3 (es)
HR (1) HRP20161398T1 (es)
HU (1) HUE030478T2 (es)
IL (1) IL213343A0 (es)
LT (1) LT2379601T (es)
MX (2) MX352117B (es)
PL (1) PL2379601T3 (es)
PT (1) PT2379601T (es)
SI (1) SI2379601T1 (es)
TW (1) TWI424162B (es)
WO (1) WO2010072384A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013177115A2 (en) * 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3176580A1 (en) 2015-12-01 2017-06-07 Roche Diagnostics GmbH Method for reduction of interferences in immunoassays
EP3508849B1 (en) * 2016-08-31 2023-04-19 Eiken Kagaku Kabushiki Kaisha Antibody measurement method using antigen-carrying insoluble carrier particles on which antigen is immobilized by different methods, and reagent for antibody measurement

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219730A (en) 1982-09-28 1993-06-15 New York University Idiotype-anti-idiotype immunoassay
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
EP0170302A1 (fr) 1984-06-27 1986-02-05 l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0243471A4 (en) 1985-10-22 1989-07-11 Cooper Lipotech Inc SOLID PHASE LIPOSOME IMMUNOANALYSIS SYSTEM.
SG60022A1 (en) 1988-11-03 1999-02-22 Igen Inc Electrochemicalmiliuminescent assays
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
JPH04507285A (ja) 1988-12-09 1992-12-17 セントコー・インコーポレーテッド 抗イディオトープ免疫検定法
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Luminescence test method and device based on magnetic tiny particles, containing many magnets
WO1994001451A2 (en) 1992-07-13 1994-01-20 Bionebraska, Inc. Method for modification of recombinant polypeptides
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
KR100767146B1 (ko) 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004092197A2 (en) 2003-04-07 2004-10-28 The Regents Of The University Of California Amyloid-specific peptides and uses thereof
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
JP2007527865A (ja) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
EP1680666A4 (en) 2003-10-27 2008-03-26 Monogram Biosciences Inc ANTI-THERAPEUTIC HUMAN ANTIBODY DETECTION
JPWO2005105998A1 (ja) 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
WO2006036291A2 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
AR051528A1 (es) 2004-12-15 2007-01-17 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AU2007222584B2 (en) 2006-03-09 2012-07-12 F. Hoffmann-La Roche Ag Anti-drug antibody assay
EP1917854A1 (en) 2006-11-06 2008-05-07 F. Hoffmann-La Roche Ag Method for producing anti idiotypic antibodies
US20080127359A1 (en) * 2006-11-06 2008-05-29 Hermann Beck Method for producing anti-idiotypic antibodies
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途

Also Published As

Publication number Publication date
AU2009331900A1 (en) 2010-07-01
CA2746779A1 (en) 2010-07-01
US9547010B2 (en) 2017-01-17
HUE030478T2 (en) 2017-05-29
SI2379601T1 (sl) 2016-11-30
BRPI0923544A2 (pt) 2016-01-26
PT2379601T (pt) 2016-10-04
EP2379601A1 (en) 2011-10-26
KR20130088199A (ko) 2013-08-07
US8614297B2 (en) 2013-12-24
CA2746779C (en) 2017-01-24
ES2595981T3 (es) 2017-01-04
JP2012513426A (ja) 2012-06-14
IL213343A0 (en) 2011-07-31
CN106990251A (zh) 2017-07-28
TW201030335A (en) 2010-08-16
BRPI0923544B1 (pt) 2021-11-23
DK2379601T3 (en) 2016-08-29
HRP20161398T1 (hr) 2016-12-16
LT2379601T (lt) 2016-10-25
CN106990251B (zh) 2019-12-27
MX352117B (es) 2017-11-09
US20100167313A1 (en) 2010-07-01
CY1118420T1 (el) 2017-06-28
CN102257010A (zh) 2011-11-23
US20130323762A1 (en) 2013-12-05
KR101777899B1 (ko) 2017-09-13
EP2379601B1 (en) 2016-08-10
WO2010072384A1 (en) 2010-07-01
PL2379601T3 (pl) 2017-02-28
JP5642702B2 (ja) 2014-12-17
KR20110086182A (ko) 2011-07-27
TWI424162B (zh) 2014-01-21
MX2011006641A (es) 2011-07-12

Similar Documents

Publication Publication Date Title
AR074816A1 (es) Anticuerpo anti- idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloide
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2013003214A1 (es) Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol.
CL2008003782A1 (es) Anticuerpo bivalente bioespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un primer antigeno donde el dominio ch3 se reemplaza por ch1, y la cadena ligera y pesada de un anticuerpo que se une a un segundo antigeno, en el que el dominio ch3 esta reemplazado por cl; metodo de preparacion; y composicion.
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
CL2013002888A1 (es) Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011).
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CU24058B1 (es) Antagonistas de pcsk9
CL2008001741A1 (es) Anticuerpo quimerico o humanizado o fragmento de los mismos que se unen especificamente a por lo menos un epitope en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados con la formacion de placas amiloides.
RS53291B (en) BETA 1-42 SPECIFIC MONOCLONIC ANTIBODIES WITH THERAPEUTIC PROPERTIES
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
CL2011002380A1 (es) Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende.
PE20141787A1 (es) Composiciones anti-cgrp y uso de las mismas
CR11691A (es) Anticuerpos monoclonales contra la proteína rgm a y sus usos
CR20120127A (es) Anticuerpos monoclonales
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
AR082630A1 (es) Anticuerpos anti-tenascina-c a2 y metodos de uso
CL2007002879A1 (es) Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure